News - MDM2 amplification

Imaging features of perinephric myxoid pseudotumors of fat. (PubMed, Abdom Radiol (NY))

PMPTF is a rare, benign, and underrecognized lesion that may mimic malignancy, particularly retroperitoneal well-differentiated liposarcoma. The imaging features of this unusual pseudosarcoma differ in native and transplanted kidneys. Improved awareness of this entity will facilitate appropriate patient management and avoid unnecessary intervention.

3 days ago

Journal

MDM2 (E3 ubiquitin protein ligase)

MDM2 amplification

22d

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)

P3, N=240, Recruiting, Boehringer Ingelheim | Initiation date: Dec 2023 --> Mar 2023

22 days ago

Trial initiation date • Metastases

MDM2 (E3 ubiquitin protein ligase)

MDM2 amplification

brigimadlin (BI 907828)

24d

Back to the future! Selected bone and soft tissue neoplasms with shared genetic alterations but differing morphological and immunohistochemical phenotypes. (PubMed, Hum Pathol)

Future classification systems in BST neoplasms cannot be solely based on molecular events and ideally will balance morphologic features with molecular analysis. Herein, we provide a narrative literature review of the more common BST neoplasms with shared genetic events but differing demographics, morphology, immunophenotype, and clinical behavior, re-emphasizing the importance of the hematoxylin and eosin slide and the "eye" of the practicing pathologist.

24 days ago

Review • Journal

MDM2 (E3 ubiquitin protein ligase) • EWSR1 (EWS RNA Binding Protein 1) • ATF1 (Activating Transcription Factor 1) • CREB1 (CAMP Responsive Element Binding Protein 1)

MDM2 amplification

Detection of MDM2 gene amplification by fluorescence in situ hybridization and its diagnostic value in low-grade osteosarcoma (PubMed, Zhonghua Bing Li Xue Za Zhi)

The interpretation criteria for FISH detection of MDM2 amplification are currently not unified. The signal characteristics need more attention when interpreting.

1 month ago

Journal

MDM2 (E3 ubiquitin protein ligase)

MDM2 amplification

2ms

Superficial dedifferentiated liposarcoma: A clinicopathologic study. (PubMed, Hum Pathol)

These findings emphasize the importance of distinguishing between primary sDDLPS and secondary lesions due to their distinct prognoses. Metastasis or superficial extensions from deep DDLP correlate with a considerably worse prognosis than those originating in superficial tissues.

2 months ago

Journal

MDM2 (E3 ubiquitin protein ligase)

MDM2 amplification

2ms

Association of MDM2 Overexpression in Ameloblastomas with MDM2 Amplification and BRAFV600E Expression. (PubMed, Int J Mol Sci)

Overexpression of MDM2 in ameloblastomas is not associated with MDM2 amplification, but most probably with MAPK activation and WTp53 expression. Further verification of those findings could form the basis for the use of MDM2 expression as a marker of MAPK activation in ameloblastomas and the trial of dual BRAF/MDM2 inhibition in the management of MDM2-overexpressing/BRAFV600E-positive/WTp53 ameloblastomas.

2 months ago

Journal

TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)

BRAF V600E • BRAF V600 • TP53 wild-type • MDM2 amplification • TP53 expression • MDM2 overexpression

2ms

DDIT3-amplified or low-polysomic pleomorphic sarcomas without MDM2 amplification: Clinicopathological review and immunohistochemical profile of nine cases. (PubMed, Hum Pathol)

The majority of cases (7/9) showed decreased expression in p53 staining, suggesting that DDIT3 amplification regulates the expression of TP53 like MDM2. From a clinicopathological perspective, we hypothesize that DDIT3-amplified sarcoma, especially with 5'-predominant amplification, can be reclassified out of the UPS category.

2 months ago

Review • Journal

TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • DDIT3 (DNA-damage-inducible transcript 3)

MDM2 amplification • TP53 expression

2ms

Primary liposarcoma of the uterus with MDM2 negative. (PubMed, Indian J Pathol Microbiol)

Immunohistochemistry showed that the tumor cells were positive for CDK4 but negative for MDM2, and FISH analysis showed no MDM2 amplification. The patient only underwent tumor excision and is currently doing well.

2 months ago

Journal

MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4)

MDM2 amplification

2ms

CDK4/MDM2 Amplification Is a Rare Targetable Genomic Event in TP53/RB1-Wildtype Uterine Leiomyosarcoma (USCAP 2024)

Overall, in our uLMS analysis, CDK4 and/or MDM2 amplification was identified in a small subset (2%) of uLMS, the majority of which are TP53/RB1-wildtype. This may suggest that CDK4/MDM2 amplification can be an alternative tumorigenic mechanism in this distinct class of uLMS, which may have therapeutic clinical implications, including possible use of specific cyclin-dependent kinase inhibitors.

2 months ago

Tumor mutational burden

TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • ATRX (ATRX Chromatin Remodeler)

TP53 mutation • MDM2 amplification • CDK4 amplification • MDM2 amplification + CDK4 amplification • RB1 wild-type • CDK4 mutation

FoundationOne® Heme CDx

2ms

Gene Fusions in Aggressive Testicular Leydig Cell Tumors Likely Represent Events Secondary to Genomic Instability without a Driver Role (USCAP 2024)

TERT fusions were not identified in this series of LCTs, with 2 aggressive metastasizing LCTs harboring non-recurrent NAV3::ASB8 and RAB3IP::TAFA2. These structural variants have not been reported previously and likely represent events secondary to genomic instability without a clear pathogenic role (PMID: 34103665). Whole transcriptome analysis is under way to elucidate additional genomic alterations present in aggressive LCTs.

2 months ago

MDM2 (E3 ubiquitin protein ligase) • NAV3 (Neuron Navigator 3 )

MDM2 amplification

TruSight RNA Pan-Cancer Panel

2ms

Genomic Insights into Bone Sarcomas Originating from Infarcts (USCAP 2024)

Bone sarcomas associated with infarcts exhibit genomic instability, with pronounced copy number variations, especially in Chromosome 12. CDKN2A/B homozygous deletion is highly prevalent, whereas TP53 alterations appear less frequent than in osteosarcomas. MDM2 amplification and H3.3-G34 mutations are recurrent (33%).

2 months ago

TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRD (Homologous Recombination Deficiency) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • DNMT3A (DNA methyltransferase 1) • MDM2 (E3 ubiquitin protein ligase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)

PIK3CA mutation • HRD • MDM2 amplification • CDKN2A deletion • HRAS mutation • HRAS G13R • PIK3CA E542K • PIK3CA E542 • HRAS G13R

TruSight Oncology 500 Assay

2ms

CDK4/MDM2 Amplification Is a Rare Targetable Genomic Event in TP53/RB1-Wildtype Uterine Leiomyosarcoma (USCAP 2024)

2 months ago

Tumor mutational burden

TP53 mutation • MDM2 amplification • CDK4 amplification • MDM2 amplification + CDK4 amplification • RB1 wild-type • CDK4 mutation

FoundationOne® Heme CDx

2ms

A Case of Myxoid Pleomorphic Liposarcoma with Rhabdoid Cells: A Diagnostic Pitfall. (PubMed, Int J Surg Pathol)

The metastatic lesions contained abundant lipoblasts rather than rhabdoid cells, and we concluded this tumor was a MPLS. The presence of rhabdoid cells could be a diagnostic pitfall, and recognizing such a variation in histology would help improve diagnostic accuracy.

2 months ago

Journal

MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • EWSR1 (EWS RNA Binding Protein 1) • FUS (FUS RNA Binding Protein) • DDIT3 (DNA-damage-inducible transcript 3) • MYOD1 (Myogenic Differentiation 1)

MDM2 amplification

2ms

Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy. (PubMed, J Biomed Sci)

Encouragingly, various MDM2 inhibitors have exhibited efficacy in relieving the TIME suppression caused by MDM2. These results demonstrate the prospects for breakthroughs in combination therapy using MDM2 inhibitors and anticancer immunotherapy.

2 months ago

Review • Journal • IO biomarker

MDM2 (E3 ubiquitin protein ligase)

MDM2 amplification

3ms

Atypical Spindle Cell/Pleomorphic Lipomatous Tumor. (PubMed, Surg Pathol Clin)

ASCPLTs lack MDM2 amplification, but a large subset show RB1 deletion and variable expression of CD34. Though initially thought to be the malignant form of spindle cell lipoma, ASCPLTs are benign with local recurrences (∼10-15%) and no well-documented dedifferentiation or metastasis.

3 months ago

Review • Journal

RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CD34 (CD34 molecule)

MDM2 amplification • RB1 deletion • RB deletion

3ms

Clinicopathological and Molecular Characteristics of IDH-Wildtype Glioblastoma with FGFR3::TACC3 Fusion. (PubMed, Biomedicines)

Our observations suggest that F3T3-positive GBM is a distinct molecular subgroup of the IDH-wildtype GBM. Both clinicians and pathologists should consider this rare entity in the differential diagnosis of diffuse astrocytic glioma to make an accurate diagnosis and to ensure appropriate therapeutic management.

3 months ago

Journal

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • TACC3 (Transforming acidic coiled-coil containing protein 3) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)

TP53 mutation • EGFR mutation • EGFR amplification • PTEN mutation • MDM2 amplification • CDKN2A deletion • CDKN2A mutation • CDK4 amplification • FGFR3 fusion • TERT mutation • IDH wild-type • TERT promoter mutation • CDK4 mutation

4ms

MDM2 FISH testing criteria in adipose tissue tumors with mature adipocytic morphology - A resection case-based study. (PubMed, Pathol Res Pract)

superficial cases with marginal infiltration based on adequate margin sampling; 2. all intramuscular tumors, retroperitoneal/pelvic tumors and recurrent tumors, both in resection cases and biopsy cases.

4 months ago

Journal

MDM2 (E3 ubiquitin protein ligase)

MDM2 amplification

4ms

Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database. (PubMed, Cancer Sci)

Of the drugs used in second-line chemotherapy for soft tissue sarcoma (STS), trabectedin is effective for liposarcoma and leiomyosarcoma (L-sarcoma), eribulin for liposarcoma, and pazopanib for non-liposarcoma. The present study demonstrated the potential of tailored therapy guided by mutation profiles established by comprehensive genomic profiling testing in optimizing second-line chemotherapy for STS. The findings of this study will hopefully contribute some valuable insights into enhancing STS treatment strategies and outcomes.

4 months ago

Journal

TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • TERT (Telomerase Reverse Transcriptase) • MDM2 (E3 ubiquitin protein ligase)

TP53 mutation • PIK3CA mutation • PTEN mutation • MDM2 amplification • MTOR mutation • TERT mutation • PIK3CA wild-type

FoundationOne® CDx

Votrient (pazopanib) • Halaven (eribulin mesylate) • Yondelis (trabectedin)

4ms

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)

P3, N=240, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

MDM2 (E3 ubiquitin protein ligase)

MDM2 amplification

brigimadlin (BI 907828)

4ms

Paratesticular Dedifferentiated Liposarcoma with Rhabdomyoblastic Differentiation: A Case Report and Review of the Literature. (PubMed, Prague Med Rep)

The surgical margins were negative, and the patient had a metastatic workup that included magnetic resonance imaging (MRI) of the abdomen and pelvis. Because of the disease's rarity, there is no clear agreement on radiotherapy and chemotherapy roles.

4 months ago

Review • Journal

MDM2 (E3 ubiquitin protein ligase)

MDM2 amplification

4ms

MDM2 amplification is rare in gastric cancer. (PubMed, Virchows Arch)

Our targeted analysis of MDM2 in a well-characterized cohort of GC patients showed that MDM2 amplification is rare, of no specific histological phenotype, and may not be always mutually exclusive with TP53 mutations. Given the low number of cases, currently, no diagnostic or therapeutic recommendation related to MDM2 amplification can be given for GC of Western origin.

4 months ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • MDM2 (E3 ubiquitin protein ligase)

TP53 mutation • FGFR2 mutation • MDM2 amplification • MDM2 mutation • TP53 amplification

4ms

Genomic characterization of unresectable/recurrent early-onset gastric cancer by comprehensive genomic profiling tests. (ASCO-GI 2024)

Among unresectable/recurrent GC population, EOCG has displayed distinct genetic profiles of GAs compared to LOGC. CGP tests may be useful in expanding treatment opportunities for patients with unresectable/recurrent EOGC.

4 months ago

Tumor mutational burden • MSi-H Biomarker

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • MDM2 (E3 ubiquitin protein ligase) • BAP1 (BRCA1 Associated Protein 1) • CDH1 (Cadherin 1) • AURKA (Aurora kinase A)

KRAS mutation • EGFR mutation • TMB-H • MSI-H/dMMR • KRAS G12C • HER-2 amplification • MET amplification • EGFR amplification • FGFR2 mutation • FGFR2 amplification • MDM2 amplification • KRAS G12 • KRAS amplification

FoundationOne® CDx • OncoGuide™ NCC Oncopanel System

4ms

Benign female genital tract smooth muscle tumors with adipocytic differentiation: A morphologic, immunohistochemical and MDM2 fluorescence in situ hybridization study of 44 conventional lipoleiomyomas and lipoleiomyoma variants. (PubMed, Hum Pathol)

MDM2 amplification fluorescence in situ hybridization performed on 14 tumors was negative in all. Our findings suggest female genital tract conventional lipoleiomyomas and lipoleiomyoma variants largely parallel their non-adipocytic counterparts in morphology and immunophenotype, and may be categorized using non-adipocytic leiomyoma histologic criteria.

4 months ago

Journal

ER (Estrogen receptor) • MDM2 (E3 ubiquitin protein ligase) • WT1 (WT1 Transcription Factor) • CTSK (Cathepsin K)

MDM2 amplification • PGR expression

4ms

Sarcomas harboring EWSR1::PATZ1 fusions: A Clinicopathologic Study of 17 Cases. (PubMed, Mod Pathol)

We conclude that the morphologic spectrum of EWSR1::PATZ1 is broader than has been previously appreciated. Although more long-term follow-up is needed, the prognosis of these very rare sarcomas may be more favorable than previously reported.

4 months ago

Journal

TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MDM2 (E3 ubiquitin protein ligase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • EWSR1 (EWS RNA Binding Protein 1) • SOX10 (SRY-Box 10) • CD99 (CD99 Molecule) • GFAP (Glial Fibrillary Acidic Protein) • MYOD1 (Myogenic Differentiation 1) • PATZ1 (POZ/BTB And AT Hook Containing Zinc Finger 1)

TP53 wild-type • MDM2 amplification • TP53 expression • TP53 amplification

5ms

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder (clinicaltrials.gov)

P2, N=155, Recruiting, Boehringer Ingelheim | Phase classification: P2a/2b --> P2

5 months ago

Phase classification

TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)

TP53 wild-type • MDM2 amplification • TP53 amplification

brigimadlin (BI 907828)

5ms

Malignant female genital tract smooth muscle tumors with adipocytic differentiation: A morphologic, immunohistochemical, MDM2 fluorescence in situ hybridization and molecular genetic study of 6 lipoleiomyosarcomas. (PubMed, Hum Pathol)

Although lipoleiomyosarcomas have a diverse morphologic spectrum, our findings suggest the smooth muscle component shares morphologic and immunohistochemical features with female genital tract non-adipocytic leiomyosarcomas. Lipoleiomyosarcomas also have genetic alterations associated with non-adipocytic gynecologic leiomyosarcomas.

5 months ago

Journal

TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • WT1 (WT1 Transcription Factor) • ATRX (ATRX Chromatin Remodeler)

TP53 mutation • MDM2 amplification

5ms

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov)

P1, N=269, Recruiting, Boehringer Ingelheim | Phase classification: P1a/1b --> P1 | N=204 --> 269

5 months ago

Phase classification • Enrollment change • Metastases

TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)

TP53 wild-type • MDM2 amplification • TP53 amplification

brigimadlin (BI 907828)

5ms

Assessment of The Utility of The Sarcoma DNA Methylation Classifier In Surgical Pathology. (PubMed, Am J Surg Pathol)

The Sarcoma Methylation Classifier will likely evolve with the addition of new entities and refinement of the present methylation classes. The classifier may also help to define new entities and give new insight into the interrelationships of sarcomas.

5 months ago

Journal • Epigenetic controller

RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • BCOR (BCL6 Corepressor)

MDM2 amplification

6ms

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)

P1/2, N=250, Active, not recruiting, Astex Pharmaceuticals, Inc. | Trial primary completion date: Jun 2025 --> Dec 2024

6 months ago

Trial primary completion date • Metastases

TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)

TP53 wild-type • MDM2 amplification

ASTX295

6ms

Liposarcoma Involving Serous Fluid Cavities-A Case Series Illustrating Clinical Implications and the Diagnostic Role of Exfoliative Cytology. (PubMed, Int J Surg Pathol)

Lipomatous and dedifferentiated components can be sampled and cytomorphologically identified on effusion fluids of liposarcomas, with sufficient cellularity for immunocytochemistry and molecular testing. Although generally associated with poor prognosis, long disease-free survival with sarcomatous effusion is possible with radical surgery and adjuvant treatment.

6 months ago

Journal • Cytology

MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4)

MDM2 amplification • CDK4 amplification • MDM2 amplification + CDK4 amplification

6ms

MANTRA-2: Milademetan in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)

P2, N=40, Terminated, Rain Oncology Inc | N=65 --> 40 | Trial completion date: Aug 2024 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Oct 2023; Sponsor Decision

6 months ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Pan tumor • Metastases

TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)

TP53 mutation • TP53 wild-type • MDM2 amplification • TP53 amplification

milademetan (RAIN-32)

7ms

Biology and Management of Deep-seated Atypical Lipomatous Tumor of the Extremities. (PubMed, Anticancer Res)

Although there is no consensus on the best surgical approach for deep-seated ALT of the extremities, the use of marginal resection is acceptable to preserve musculoskeletal function. This review provides an overview of the current knowledge on the clinical and imaging characteristics, pathogenesis, histopathology, and management of deep-seated ALT of the extremities.

7 months ago

Review • Journal

MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4)

MDM2 amplification

7ms

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)

P3, N=240, Not yet recruiting, Boehringer Ingelheim

7 months ago

New P3 trial • Metastases

MDM2 (E3 ubiquitin protein ligase)

MDM2 amplification

brigimadlin (BI 907828)

7ms

PDLIM7 GENE INTERACTS WITH MDM2 IN ADVANCED THYROID CANCER (ATA 2023)

Enigma‐MDM2 correlation and interaction were observed in advanced TC samples. Further research is needed to understand its precise mechanisms and potential as a therapeutic target in thyroid cancer.

7 months ago

Late-breaking abstract • Metastases

MDM2 (E3 ubiquitin protein ligase) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • PI3K (Phosphoinositide 3-kinases)

MDM2 amplification

7ms

Primary cardiac sarcomas: A clinicopathologic study in a single institution with 25 years of experience with an emphasis on MDM2 expression and adjuvant therapy for prognosis. (PubMed, Cancer Med)

Our study supports the use of adjuvant treatment in primary cardiac sarcoma, as it was associated with a significantly better overall survival rate. Further consideration of tumor histology may be important in determining the optimal use of adjuvant treatment for different types of sarcomas. Therefore, accurate diagnosis by MDM2 test is important condsidering patient's prognosis and treatment.

7 months ago

Journal

MDM2 (E3 ubiquitin protein ligase)

MDM2 amplification

7ms

A novel HMGA2::KITLG fusion in a dedifferentiated liposarcoma with amplification of MDM2 and HMGA2. (PubMed, Genes Chromosomes Cancer)

We suggest an oncogenic mechanism that involves the overexpression of KITLG caused by its rearrangement with HMGA2, leading to the constitutive activation of KIT kinase. While MDM2 amplification was observed in both the primary tumor and the relapsed tumor, the HMGA2::KITLG was only present in the relapsed tumor, indicating the role of HMGA2::KITLG in disease progression.

7 months ago

Journal

MDM2 (E3 ubiquitin protein ligase) • HMGA2 (High mobility group AT-hook 2)

MDM2 amplification • KIT expression • KIT fusion

7ms

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)

P1/2, N=250, Active, not recruiting, Astex Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting

7 months ago

Enrollment closed • Metastases

TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)

TP53 wild-type • MDM2 amplification

ASTX295

7ms

Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)

P2/3, N=386, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting

7 months ago

Enrollment closed • Metastases

MDM2 (E3 ubiquitin protein ligase)

MDM2 amplification

doxorubicin hydrochloride • brigimadlin (BI 907828)